FOOD AND DRUG ADMINISTRATION (FDA)

Center for Drug Evaluation and Research (CDER)

Peripheral and Central Nervous System Drugs Advisory Committee (PCNS) Meeting

FDA White Oak Campus, Building 31 Conference Center, the Great Room (Rm. 1503) 10903 New Hampshire Avenue, Silver Spring, Maryland November 24, 2015

DRAFT MEETING ROSTER

ACTING DESIGNATED FEDERAL OFFICER (Non-Voting)

Philip A. Bautista, PharmD

Division of Advisory Committee and Consultant Management Office of Executive Programs, CDER, FDA

PERIPHERAL AND CENTRAL NERVOUS SYSTEM DRUGS ADVISORY COMMITTEE **MEMBERS** (Voting)

G. Caleb Alexander, MD, MS

(Chairperson)

Associate Professor of Epidemiology and Medicine Department of Health Evidence and Policy Johns Hopkins School of Public Health Center for Drug Safety and Effectiveness

Baltimore, Maryland

Nicole R. Gonzales, MD

Associate Professor University of Texas-Houston Medical School Department of Neurology – Stoke Program Houston, Texas

Michelle M. Mielke, PhD

Associate Professor Division of Epidemiology Department of Health Sciences Research Mayo Clinic Rochester, Minnesota

Bruce I. Ovbiagele, MD, MSc, MAS

Professor and Chairman of Neurology Medical University of South Carolina Charleston, South Carolina

Emilia Bagiella, PhD

Professor of Biostatistics Mount Sinai School of Medicine Icahn Medical Institute New York, New York

Richard P. Hoffmann, PharmD

(Consumer Representative) Drug Information Consultant/ Medical Writer Hernando, Florida

Chiadi U. Onvike, MD

Associate Professor of Psychiatry and Behavioral Sciences Division of Geriatric Psychiatry and Neuropsychiatry Department of Psychiatry and Behavioral Sciences The Johns Hopkins University School of Medicine Baltimore, Maryland

Justin A. Zivin, MD

Professor Emeritus Department of Neurosciences Rancho Santa Fe, California

FOOD AND DRUG ADMINISTRATION (FDA)

Center for Drug Evaluation and Research (CDER)

Peripheral and Central Nervous System Drugs Advisory Committee (PCNS) Meeting November 24, 2015

DRAFT MEETING ROSTER (cont.)

TEMPORARY MEMBERS (Voting)

Christopher Cassidy

(Patient Representative) Annandale, Virginia

A. Reghan Foley, MD

Staff Clinician Neuromuscular and Neurogenetic Disorders of Childhood Section, Neurogenetics Branch Division of Intramural Research National Institute of Neurological Disorders of Stroke (NINDS) National Institutes of Health (NIH) Bethesda, Maryland

Cheri Gunvalson, RN, MS

(Patient Representative) Clinical Assistant Professor University of North Dakota, College of Nursing Grand Forks, North Dakota

Aaron S. Kesselheim, MD, JD, MPH

Associate Professor of Medicine Harvard Medical School Director, Program on Regulation, Therapeutics, and Committee, Neurogenetics Cluster Law (PORTAL) Division of Pharmacoepidemiology and Pharmacoeconomics Brigham & Women's Hospital Boston, Massachusetts

Paul Romitti, PhD

Professor Department of Epidemiology and Interdisciplinary Program in Toxicology University of Iowa Iowa City, Iowa

Michelle M. Estrella, MD, MHS

Attending Nephrologist Bayview Medical Center and Johns Hopkins Hospital Associate Faculty member at the Welch Center for Prevention, Epidemiology, and Clinical Research Baltimore, Maryland

Mark W. Green, MD, FAAN

Professor of Neurology, Anesthesiology, and Rehabilitation Medicine Director of Headache and Pain Medicine Icahn School of Medicine at Mt Sinai New York, New York

Rodney L. Levine, MD, PhD

Chief Section on Protein Function in Disease Laboratory of Biochemistry National Heart, Lung, and Blood Institute, NIH Bethesda, Maryland

Glen Nuckolls, PhD

Program Director and Executive Secretary Interagency Muscular Dystrophy Coordinating Division of Extramural Research NINDS, NIH Bethesda, Maryland

FOOD AND DRUG ADMINISTRATION (FDA)

Center for Drug Evaluation and Research (CDER)

Peripheral and Central Nervous System Drugs Advisory Committee (PCNS) Meeting November 24, 2015

DRAFT MEETING ROSTER (cont.)

ACTING INDUSTRY REPRESENTATIVE TO THE COMMITTEE (Non-Voting)

Mark Gordon, MD

(Acting Industry Representative)
Director, Clinical Development and Medical Affairs
General Medicine/Central Nervous Systems
Boehringer Ingelheim Pharmaceuticals
Ridgefield, Connecticut

FDA PARTICIPANTS (Non-Voting)

Ellis Unger, MD

Director Office of Drug Evaluation I (ODE I) Office of New Drugs (OND), CDER, FDA

Billy Dunn, MD

Director Division of Neurology Products (DNP) ODE I, OND, CDER, FDA

Ronald Farkas, MD, PhD

Clinical Team Leader DNP, ODE I, OND, CDER, FDA

Robert Temple, MD

Deputy Director ODE I, OND, CDER, FDA

Eric Bastings, MD

Deputy Director DNP, ODE I, OND, CDER, FDA